Examkin

Question

Difficulty: EasyMedical Literature and Drug Advertisement Interpretation

A physician is reviewing a pharmaceutical advertisement for a newly approved medication, cardiopril, intended for patients with stable coronary artery disease. The advertisement features a prominent graph highlighting a "30%30\% relative risk reduction in major adverse cardiovascular events (MACE)" with a highly significant p-value (p<0.01p < 0.01). To better understand the clinical impact, the physician examines the data table detailing the individual components of the composite MACE endpoint over the 5-year study period.

Endpoint ComponentPlacebo (n=1000)Cardiopril (n=1000)p-value
Cardiovascular mortality4.2%4.2\%4.1%4.1\%0.850.85
Nonfatal myocardial infarction5.5%5.5\%5.3%5.3\%0.720.72
Hospitalization for angina11.3%11.3\%5.3%5.3\%<0.01< 0.01
Overall Composite (MACE)21.0%21.0\%14.7%14.7\%<0.01< 0.01

Based on the data provided, which of the following is the most accurate interpretation of the advertisement's efficacy claim?

  1. The overall statistically significant benefit of the medication is primarily driven by a reduction in hospitalizations for angina.Answer
  2. B
    The medication significantly reduces the risk of cardiovascular mortality compared to placebo.
  3. C
    The use of a composite endpoint in this study invalidates the statistical significance of the overall findings.
  4. D
    The trial demonstrates an effect modification where cardiovascular mortality negatively confounds the angina outcomes.
  5. E
    The medication is contraindicated in patients with a history of nonfatal myocardial infarction due to an increased event rate.

Answer

The overall statistically significant benefit of the medication is primarily driven by a reduction in hospitalizations for angina.
When evaluating a clinical trial that uses a composite primary endpoint (such as MACE), it is essential to examine the individual components that make up the composite. Pharmaceutical advertisements often highlight the overall significant reduction. In this scenario, while the composite MACE is significantly reduced (p<0.01p < 0.01), the more severe components (cardiovascular mortality and nonfatal myocardial infarction) were not significantly affected by the drug (p=0.85p = 0.85 and p=0.72p = 0.72, respectively). The only component with a statistically significant reduction is hospitalization for angina (p<0.01p < 0.01). Therefore, the drug's apparent overall benefit is driven entirely by a reduction in a less severe morbidity outcome, which is a common phenomenon in cardiovascular trials.

Step-by-Step Solution

1
Evaluate the overall trial outcome
The overall composite endpoint (MACE) is statistically significant (p<0.01p < 0.01).
This confirms the advertisement's primary claim is mathematically true, prompting further investigation into its clinical meaning.
2
Analyze the individual components of the composite endpoint
Cardiovascular mortality (p=0.85p = 0.85) and nonfatal myocardial infarction (p=0.72p = 0.72) show no statistically significant difference.
P-values greater than 0.050.05 indicate that the observed differences in these severe outcomes are likely due to chance.
3
Identify the driver of the composite significance
Hospitalization for angina shows a highly significant reduction (11.3%11.3\% vs 5.3%5.3\%, p<0.01p < 0.01).
Because it is the only individual component with a significant p-value, it must be the primary driver of the overall composite significance.

Key Concept

Evaluating components of composite endpoints in medical literature
Estimated Time:1m 0s
Rate this question

Topics

Medical Literature and Drug Advertisement Interpretation

More questions from this topic